O'Hagan DT - Search Results

1

Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization.

Francica JR, Sheng Z, Zhang Z, Nishimura Y, Shingai M, Ramesh A, Keele BF, Schmidt SD, Flynn BJ, Darko S, Lynch RM, Yamamoto T, Matus-Nicodemos R, Wolinsky D; NISC Comparative Sequencing Program; Nason M, Valiante NM, Malyala P, De Gregorio E, Barnett SW, Singh M, O'Hagan DT, Koup RA, Mascola JR, Martin MA, Kepler TB, Douek DC, Shapiro L, Seder RA. Francica JR, et al. Nat Commun. 2015 Apr 10;6:6565. doi: 10.1038/ncomms7565. Nat Commun. 2015. PMID: 25858157 Free PMC article.

2

The path to a successful vaccine adjuvant--'the long and winding road'.

O'Hagan DT, De Gregorio E. O'Hagan DT, et al. Drug Discov Today. 2009 Jun;14(11-12):541-51. doi: 10.1016/j.drudis.2009.02.009. Epub 2009 Mar 5. Drug Discov Today. 2009. PMID: 19508916 Review.

3

Vaccine adjuvant formulations: a pharmaceutical perspective.

Brito LA, Malyala P, O'Hagan DT. Brito LA, et al. Semin Immunol. 2013 Apr;25(2):130-45. doi: 10.1016/j.smim.2013.05.007. Epub 2013 Jul 12. Semin Immunol. 2013. PMID: 23850011 Review.

4

Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake.

Liang F, Lindgren G, Sandgren KJ, Thompson EA, Francica JR, Seubert A, De Gregorio E, Barnett S, O'Hagan DT, Sullivan NJ, Koup RA, Seder RA, Loré K. Liang F, et al. Sci Transl Med. 2017 Jun 7;9(393):eaal2094. doi: 10.1126/scitranslmed.aal2094. Sci Transl Med. 2017. PMID: 28592561

5

Gaps in knowledge and prospects for research of adjuvanted vaccines.

Seder R, Reed SG, O'Hagan D, Malyala P, D'Oro U, Laera D, Abrignani S, Cerundolo V, Steinman L, Bertholet S. Seder R, et al. Vaccine. 2015 Jun 8;33 Suppl 2:B40-3. doi: 10.1016/j.vaccine.2015.03.057. Vaccine. 2015. PMID: 26022566

6

Recent advances in vaccine adjuvants.

Singh M, O'Hagan DT. Singh M, et al. Pharm Res. 2002 Jun;19(6):715-28. doi: 10.1023/a:1016104910582. Pharm Res. 2002. PMID: 12134940 Review.

7

Recent advances in the discovery and delivery of vaccine adjuvants.

O'Hagan DT, Valiante NM. O'Hagan DT, et al. Nat Rev Drug Discov. 2003 Sep;2(9):727-35. doi: 10.1038/nrd1176. Nat Rev Drug Discov. 2003. PMID: 12951579 Free PMC article. Review.

8

Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles.

Malyala P, O'Hagan DT, Singh M. Malyala P, et al. Adv Drug Deliv Rev. 2009 Mar 28;61(3):218-25. doi: 10.1016/j.addr.2008.12.009. Epub 2009 Jan 11. Adv Drug Deliv Rev. 2009. PMID: 19168103 Review.

9

The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant.

Jain S, O'Hagan DT, Singh M. Jain S, et al. Expert Rev Vaccines. 2011 Dec;10(12):1731-42. doi: 10.1586/erv.11.126. Expert Rev Vaccines. 2011. PMID: 22085176 Free article. Review.

10

Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.

Francica JR, Zak DE, Linde C, Siena E, Johnson C, Juraska M, Yates NL, Gunn B, De Gregorio E, Flynn BJ, Valiante NM, Malyala P, Barnett SW, Sarkar P, Singh M, Jain S, Ackerman M, Alam M, Ferrari G, Salazar A, Tomaras GD, O'Hagan DT, Aderem A, Alter G, Seder RA. Francica JR, et al. Blood Adv. 2017 Nov 17;1(25):2329-2342. doi: 10.1182/bloodadvances.2017011411. eCollection 2017 Nov 28. Blood Adv. 2017. PMID: 29296883 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

216 results

Search Page

Filters